 Evidence continues to accumulate on the importance of inflammation in the development and progression of heart failure HF. The CelacadeTM system may reduce chronic inflammation by stimulating the immune systems physiological anti-inflammatory response. The ACCLAIM study is an international, approximately 2,000-patient, Phase III clinical research study designed to test the safety and efficacy of the CelacadeTM system in reducing the risk of mortality and cardiovascular hospitalizations in patients with chronic systolic HF. 